Interestingly, trials with a CXCR4-targeted antibody developed by Bristol-Myers Squibb, Ulocuplumab, supported further clinical development for use in Waldenstrom’s macroglobulinemia and multiple myeloma (Table 4) [277, 278]. Here, CXCR4 is linked to AL amyloidosis.